Poolbeg Pharma Plc

Poolbeg Pharma is a clinical-stage pharmaceutical company focused on the development and commercialisation of therapies to treat and prevent infectious diseases. Headquartered in London, the business is a spin out from Open Orphan Plc and the management team has proven capabilities in identifying, acquiring and accelerating assets through development to commercialisation. It has adopted a capital-light model which enables it to develop multiple products faster and more cost effectively than the traditional biotech model, and the company aspires to become a “one-stop shop” for big pharma to find Phase II ready products for development and commercialisation.

The company’s lead asset is POLB 001, a drug with the potential to treat serious unmet needs in patients suffering from severe influenza.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.